Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study

Scientific paper - Original scientific paper

• Author: Ahmad Albshesh
• Author: Joshua Taylor
• Author: Edoardo V. Savarino
• Author: Marie Truyens
• Author: Alessandro Armuzzi
• Author: Davide G. Ribaldone
• Author: Ariella Bar-Gil Shitrit
• Author: Morine Fibelman
• Author: Pauliina Molander
• Author: Claire Liefferinckx
• Author: Stephane Nancey
• Author: Mohamed Korani
• Author: Mariann Rutka
• Author: Manuel Barreiro-de Acosta
• Author: Viktor Domislovic
• Author: Gerard Suris
• Author: Carl Eriksson
• Author: Catarina Alves
• Author: Afroditi Mpitouli
• Author: Caroline di Jiang
• Author: Katja Tepeš
• Author: Marina Coletta
• Author: Kalliopi Foteinogiannopoulou
• Author: Javier P. Gisbert
• Author: Hadar Amir-Barak
• Author: Mohamed Attauabi
• Author: Jakob Seidelin
• Author: Waqqas Afif
• Author: Carla Marinelli
• Author: Triana Lobaton
• Author: Daniela Pugliese
• Author: Nitsan Maharshak
• Author: Anneline Cremer
• Author: Jimmy K. Limdi
• Author: Tamás Molnár
• Author: Borja Otero-Alvarin
• Author: Željko Krznarić; MBZ: 75865
• Author: Fernando Magro
• Author: Konstantinos Karmiris
• Author: Tim Raine
• Author: David Drobne
• Author: Ioannis Koutroubakis
• Author: Maria Chaparro
• Author: Henit Yanai
• Author: Johan Burisch
• Author: Uri Kopylov
• Author's institution: University of Zagreb; School of Medicine; (Department of Internal Medicine)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Internal Medicine

Abstract (english)

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described.
-----
Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD.
-----
Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5).
-----
Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

• Keywords (english): Crohn’s disease; anti-TNF failure; treatment failure; treatment response; ustekinumab; vedolizumab
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Journal of Clinical Medicine
• Numbering: vol. 10, no. 13, 2914
• e-ISSN: 2077-0383
• DOI: https://doi.org/10.3390/jcm10132914
• URN:NBN: urn:nbn:hr:105:153868
• Publication: 2021-06-29
• Document URL: https://www.mdpi.com/2077-0383/10/13/2914
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-06-10 09:42:00